User profiles for R. Cordoba

Raul Cordoba

- Verified email at fjd.es - Cited by 3947

Rosa Córdoba

- Verified email at uv.es - Cited by 2622

Review of magnetic nanostructures grown by focused electron beam induced deposition (FEBID)

…, A Fernández-Pacheco, R Córdoba… - Journal of Physics D …, 2016 - iopscience.iop.org
We review the current status of the use of focused electron beam induced deposition (FEBID)
for the growth of magnetic nanostructures. This technique relies on the local dissociation of …

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic …

…, G Boriani, D Cardinale, R Cordoba… - European Heart …, 2022 - academic.oup.com
ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified that,
unless otherwise provided for by national regulations, offlabel use of medication should be …

Immunotherapy in older adults with advanced cancers: implications for clinical decision-making and future research

R Kanesvaran, R Cordoba, R Maggiore - American Society of Clinical …, 2018 - ascopubs.org
Immunotherapy has expanded the therapeutic landscape for advanced cancers, including
solid tumors and lymphomas. For many patients with cancer, these agents have been shown …

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

…, SS Skånland, R Cordoba… - Blood, The Journal …, 2020 - ashpublications.org
Given advanced age, comorbidities, and immune dysfunction, chronic lymphocytic leukemia
(CLL) patients may be at particularly high risk of infection and poor outcomes related to …

[HTML][HTML] Frailty assessment in the care of older people with haematological malignancies

…, FJ Martinez-Peromingo, R Cordoba - The Lancet Healthy …, 2021 - thelancet.com
… In these studies, these three tools were predictive of inferior outcomes after treatment of
non-Hodgkin lymphoma with chemoimmunotherapy plus lenalidomide or R-CHOP (rituximab …

[HTML][HTML] COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

…, D Bron, A Capasso, S Chatzileontiadou, R Cordoba… - Leukemia, 2021 - nature.com
Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus
disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. …

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study

…, M Yağci, NA Horowitz, P Marlton, R Cordoba… - The Lancet …, 2019 - thelancet.com
Background Preclinical studies have shown synergistic antitumour effects between ibrutinib
and immune-checkpoint blockade. The aim of this study was to assess the safety and activity …

Outcome of infection with omicron SARS‐CoV‐2 variant in patients with hematological malignancies: an EPICOVIDEHA survey report

…, M Sciumè, E Ammatuna, R Cordoba… - American journal of …, 2022 - Wiley Online Library
To the Editor: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has
caused high mortality in patients with hematological malignancies (HM). 1 The newly …

Stigma and functioning in patients with bipolar disorder

…, F Kapczinski, PV Magalhaes, R Córdoba… - Journal of affective …, 2011 - Elsevier
OBJECTIVE: The aim of this study was to investigate the impact of self-rated stigma and
functioning in patients with bipolar disorder in Latin-America. METHODS: Two-hundred and forty-…

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

…, KA Rogers, JN Allan, R Cordoba… - Blood, The Journal …, 2021 - ashpublications.org
COI notes: LER has served as a consultant for AbbVie, AstraZeneca, Pharmacyclics, Vaniam
group, and Verastem, holds minority ownership interest in Abbott Laboratories, and has …